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KESAN POLIMORFISMA CYP3A4 DAN CYP3A5 KE ATAS 
FARMAKOKINETIK DAN FARMAKODINAMIK ANASTROZOLE DI 
KALANGAN PESAKIT-PESAKIT KANSER PAYUDARA 
PASCAMENOPAUS 
 
ABSTRAK 
 
Kanser payudara adalah kanser yang kedua paling kerap di antara semua jenis kanser 
dan paling biasa berlaku di kalangan wanita. Anastrozole merupakan salah satu ubat 
barisan hadapan pilihan untuk rawatan kanser payudara dan dipercayai lebih unggul 
berbanding dengan tamoxifen. Walau bagaimanapun, sebahagian besar pesakit-
pesakit yang dirawat dengan anastrozole mengalami keberulangan laku kanser 
payudara atau pun terjadinya kesan-kesan mudarat ubat yang teruk. Kebolehubahan 
antara pesakit ini adalah disebabkan oleh beberapa faktor seperti variasi genetik. 
Anastrozole secara umumnya dimetabolisme oleh enzim-enzim CYP3A4 dan 
CYP3A5. Tujuan kajian ini adalah untuk menentukan kesan polimorfisme genetik 
CYP3A4 dan CYP3A5 ke atas farmakokinetik dan farmakodinamik anastrozole di 
kalangan pesakit kanser payudara wanita. Sejumlah 94 pesakit kanser payudara 
wanita pasca-menopaus telah direkrut untuk kajian ini. Data-data demografi sosial 
dan pembolehubah-pembolehubah klinikal telah direkodkan dan sampel-sampel 
darah telah dikumpul untuk pemerolehan DNA, sukatan aras hormon dan aras 
anastrozole dalam serum. Pengenotipan CYP3A4*18A dan CYP3A5*3 telah 
dilakukan dengan menggunakan kaedah tindak balas berantai polimerase-
polimorfisme cebisan pemotongan panjang (PCR - RFLP) konvensional, manakala 
pengenotipan CYP3A4*4, CYP3A4*18B dan CYP3A4*22 pula menggunakan kaedah 
 xxiv 
 
PCR-RFLP multipleks. Kepekatan anastrozole dalam serum telah ditentukan dengan 
menggunakan kaedah kromatografi cecair resolusi pantas (UHPLC) yang baru 
dibangunkan berserta prosedur ekstraksi fasa pepejal ringkas. Kajian kami 
melaporkan bahawa CYP3A4*18B G>A berkerapan yang tinggi (0.48) di kalangan 
penduduk Malaysia manakala CYP3A4*18A T>C dan CYP3A5*3 A>G masing-
masing muncul dalam kekerapan rendah (0.03) dan tinggi (0.64) di kalangan 
penduduk Malaysia. Tiada alel-alel varian CYP3A4*4 dan CYP3A4*22 dikesan di 
kalangan subjek. Pesakit-pesakit yang mempunyai CYP3A4*18B G>A dan 
CYP3A5*3 A>G homozigot masing-masing mempunyai paras anastrozole dalam 
serum yang rendah dan tinggi berbanding dengan mereka yang mempunyai varian-
varian jenis liar dan heterozigot. Kaedah multipleks PCR-RFLP untuk pengesanan 
serentak CYP3A4*4 A>G, CYP3A4*18B G>A dan CYP3A4*22 C>T tersebut 
diaplikasikan untuk pengenotipan kesemua subjek. Kaedah UHPLC yang baru 
dibangunakan tersebut menunjukkan lienariti yang baik antara julat kepekatan 20 dan 
1600 ng/mL. Purata kepersisan untuk anastrozole adalah 88.17% dengan limit 
kuantifikasi sebanyak 20 ng/mL. Pembolehubah-pembolehubah seperti umur pesakit 
dan jangka masa semenjak permulaan rawatan anastrozole adalah masing-masing 
berhubung kait dengan risiko yang lebih tinggi untuk berlakunya simptom-simptom 
vasomotor dan gangguan-gangguan ragam dan/atau kekeringan faraj/dispareunia. 
Tiada hubung kait yang ketara di antara polimorfisme-polimorfisme genetik CYP3A4 
dan CYP3A5 dan farmakodinamik anastrozole. Alel CYP3A4*18B G>A dan 
CYP3A5*3 A>G boleh digunakan sebagai biomarker yang penting dalam 
mempengarahi metabolisme anastrozole di kalangan pasakit kanser payudara 
pascamenopaus di masa hadapan.  
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THE IMPACT OF CYP3A4 AND CYP3A5 POLYMORPHISMS ON 
ANASTROZOLE’S PHARMACOKINETICS AND PHARMACODYNAMICS 
IN POST-MENOPAUSAL BREAST CANCER PATIENTS 
 
ABSTRACT 
Breast cancer is the second most frequent cancer among all cancer types and is by far 
the commonest cancer in women. Anastrozole is one of the first line drugs of choice 
in the treatment of breast cancer and is believed to be superior to tamoxifen. 
However, a significant proportion of patients treated with anastrozole experienced 
recurrences of breast cancer or developed severe adverse drug reactions. This inter-
patient variability is attributed to a number of factors such as genetic variations. 
Anastrozole is predominantly metabolized by CYP3A4 and CYP3A5 enzymes. The 
objective of this study was to determine the impact of CYP3A4 and CYP3A5 genetic 
polymorphisms on anastrozole’s pharmacokinetics and pharmacodynamics in post-
menopausal breast cancer women. A total of 94 postmenopausal breast cancer 
women were recruited for this study. Patients’ socio-demographic data and clinical 
variables were recorded and blood samples were collected for DNA acquisition, 
hormonal and anastrozole serum levels. Genotyping of CYP3A4*18A and CYP3A5*3 
was performed using the conventional polymerase chain reaction-restriction 
fragment length polymorphism (PCR-RFLP), while that of CYP3A4*4, 
CYP3A4*18B and CYP3A4*22 was carried out by a novel multiplex PCR-RFLP 
method. Serum anastrozole concentration was determined by an ultra-high 
performance liquid chromatography (UHPLC) method using a simple solid-phase 
extraction procedure. Our study reported that CYP3A4*18B G>A has a high 
frequency (0.48) among Malaysians and that CYP3A4*18A T>C and CYP3A5*3 
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A>G occur in low (0.03) and high (0.64) frequencies respectively among 
Malaysians. No variant alleles of CYP3A4*4 and CYP3A4*22 were detected among 
all the subjects. Patients homozygous for CYP3A4*18B G>A and CYP3A5*3 A>G 
had lower and higher anastrozole serum levels respectively compared to those having 
the respective wild types or heterozygous variants. The multiplex PCR-RFLP method 
for the simultaneous detection of CYP3A4*4 A>G, CYP3A4*18B G>A and 
CYP3A4*22 C>T, was applied in genotyping of all the subjects. The newly 
developed UHPLC method demonstrated a good linearity over concentration ranges 
of 20 – 1600 ng/mL. The mean recovery for anastrozole was 88.17% with a limit of 
quantitation of 20 ng/ml. Variables such as patients’ age and time since 
commencement of anastrozole therapy were associated with higher risk of 
developing vasomotor symptoms and mood disturbances and/or vaginal 
dryness/dyspareunia respectively. No significant association was established between 
CYP3A4 and CYP3A5 genetic polymorphisms and anastrozole’s pharmacodynamics. 
The detected CYP3A4*18B G>A and CYP3A5*3 A>G alleles may serve as an 
important biomarkers of altered anastrozole metabolism in breast cancer patients 
receiving anastrozole in future.  
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CHAPTER ONE 
 
INTRODUCTION 
 
1.1 Background  
 
Globally, breast cancer is the second most common cancer and by is far the most 
frequent cancer in women with estimated 1.3 million cases and approximately 
500,000 deaths reported annually (WHO, 2015). However, in terms of mortality, it 
ranks fifth as a result of fairly favourable prognosis (Ferlay et al., 2015). In general, 
cancer can be regarded as a genetic disease (Workman, 2002; Gilbertson, 2011). Its 
well-known complex interactions between an individual’s genome and the 
environment play a crucial role in the development of breast cancer (Hankinson et 
al., 2004; Song et al., 2011; Forman et al., 2015). Both oestrogen biosynthesis 
pathway and oestrogen receptors are important therapeutic targets for breast cancer 
in which prolonged exposure to oestrogen has been implicated in the aetiology of 
breast cancer (Key et al., 2002; Brown and Hankinson, 2015). 
 
Physiologically, oestrogen plays a key role in the regulation of mammary gland 
development (Lamote et al., 2004; Musumeci et al., 2015). Two ligand-dependent 
transcription factors designated as oestrogen receptor alpha (ERα) and oestrogen 
receptor beta (ERβ) are the major transducers of oestrogen physiological effect. ERβ 
are expressed in approximately 70% of breast tumours, while the majority of breast 
tumours co-express both ERα and ERβ (Dotzlaw et al., 1997; Fuqua et al., 2003; 
Huang et al., 2015). ERα stimulates the growth of breast cells while ERβ exerts the 
opposite effect by enhancing anti-proliferative and pro-apoptotic functions (Liu et 
al., 2002; Paruthiyil et al., 2004; Strom et al., 2004). 
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The rate-limiting and final step of oestrogen biosynthesis is catalysed by an enzyme 
called the aromatase (CYP19A1) (Simpson et al., 1994; Gennari et al., 2011). The 
source of oestrogen varies significantly depending on the menopausal status of a 
woman. In pre-menopausal women, the principal source of oestrogen is the ovary 
while in post-menopausal women (when the production of oestrogen by the ovary 
ceases) oestrogen is synthesized by a number of extra-gonadal locations such as the 
adipose tissue, breast, brain, liver, and muscle  (van Landeghem et al., 1985; 
Simpson et al., 1994; Gennari et al., 2011; Lonning et al., 2011). 
 
Until recently, tamoxifen has been the drug of choice as an adjuvant therapy for both 
pre- and postmenopausal women with oestrogen receptor-positive early breast cancer 
(Montemurro et al., 2015; Li and Shao, 2016). Although tamoxifen is still an 
indispensable therapeutic option in both pre- and post-menopausal women with 
breast cancer (Pan and Chlebowski, 2014), its long term use has raised concerns 
owing to its association with potentially life-threatening adverse effects such as 
increasing incidence of endometrial cancer, thromboembolism and cerebrovascular 
events (Braithwaite et al., 2003; Fisher et al., 2005; Lewis, 2007; Perez, 2007; Ryden 
et al., 2016). In addition, some proportion of women with breast cancer can be 
primarily resistant to tamoxifen or may, in due course become resistant to it even if 
they previously expressed high levels of oestrogen receptors (Normanno et al., 2005; 
Zilli et al., 2009; Hayes and Lewis-Wambi, 2015). These recent concerns provided 
justification for introducing alternative endocrine therapies for treatment of hormone-
responsive postmenopausal breast cancer and inhibition of aromatase has become a 
prevailing current of thought in the treatment of these cases (Wood et al., 2003; 
Normanno et al., 2005; Zilli et al., 2009; Li and Shao, 2016). Consequently, a 
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number of aromatase inhibitors (AIs) have been developed to either serve as 
alternative to or be used following a few years of tamoxifen treatment and the current 
guidelines recommend the use of third-generation AIs (anastrozole, exemestene and 
letrozole) which are highly specific to the aromatase enzyme and have fewer adverse 
effects when compared with previous generations of AIs (Fabian, 2007; Goldhirsch 
et al., 2009; NCCN, 2012).  
 
Anastrozole, which is a non-steroidal third-generation aromatase inhibitor is an 
achiral triazole derivative known as 2,2' [5-(1H- 1,2,4-triazol- 1-ylmethyl)- 1,3-
phenylene]bis(2-methylpropiononitrile) and has been reported to suppress plasma 
oestradiol optimally when administered at 1 to 10 mg/day with both doses capable of 
suppressing the oestradiol completely (Plourde et al., 1994; Wood et al., 2003). The 
mechanism of action of anastrozole is by inhibition or inactivation of aromatase with 
consequent inhibition of conversion of androgens to oestrone and oestradiol in 
peripheral tissues as well as in a few sites of the central nervous system (Simpson, 
2003; Wood et al., 2003). 
 
Anastrozole is a well-established drug of choice for a variety of clinical settings 
ranging from breast cancer chemoprevention to treatment of postmenopausal women 
with early-stage breast cancer in both the adjuvant setting and advanced-stage 
disease (Chumsri, 2015). In the Arimedex, Tamoxifen Alone or in Combination trial 
(ATAC), anastrozole was shown to be more efficacious and less toxic (Cuzick et al., 
2010) than tamoxifen. It was on this basis that anastrozole was approved by the US 
Food and Drug Administration in 2002 for use in the adjuvant setting to treat women 
with early-stage endocrine-sensitive breast cancer and is therefore currently 
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considered as the first-line drug of choice for this indication (Behan et al., 2015). 
Anastrozole has shown some encouraging results in the initial therapy setting (Forbes 
et al., 2008), following two to three years of tamoxifen (Boccardo et al., 2005; 
Jakesz et al., 2005; Kaufmann et al., 2007) and as in the extended adjuvant after five 
years of tamoxifen (Jakesz et al., 2007). 
 
The primary site of anastrozole clearance is in the liver (Ingle et al., 2010a) where it 
is oxidized by CYP3A4 to form hydroxyl anastrozole, which may further be 
glucuronidated to hydroxyl anastrozole by UGT1A4, alternatively, it can also be 
directly glucuronidated to anastrozole N-glucuronide and the conjugation reaction is 
mainly catalyzed by UGT1A4 and to a lesser degree by UGT2B7 and UGT1A3 
(Kamdem et al., 2010; Lazarus and Sun, 2010). Anastrozole is also metabolised to 
some extent by CYP3A5 and to a negligible extent by CYP2C8 (Kamdem et al., 
2010). 
 
The current trend in personalized treatment include among other approaches genetic 
testing to investigate a patient’s ability to effectively metabolize drugs which have 
resulted in improved dosing of medications for many disease conditions (PMC, 
2011). Genetic polymorphisms affect metabolism causing either increased drug 
toxicity or decreased efficacy of not only the drug but its metabolites (Vogel et al., 
2013). It has recently been reported that sequencing analysis of UGT1A4 promoter 
(non-coding) region from the liver specimens of 96 human subject demonstrated the 
presence of four SNPs variants of varying frequencies i.e., rs77588960 (0.07), 
rs11876575 (0.13), rs2074746 (0.08) and -219C>T (0.16) in which interestingly 
three of these SNPs (rs11876575, rs2074746 and -219C>T exhibited significant 
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association with anastrozole glucuronidation (Edavana et al., 2013). However, to 
date, no data on the impact of CYP3A4 and CYP3A5 single nucleotide 
polymorphisms (SNPs) on anastrozole’s pharmacokinetics and pharmacodynamics 
exists. 
 
1.2 Problem statement  
 
Although it has been clearly demonstrated that anastrozole is superior and more 
efficacious than tamoxifen (Cuzick et al., 2010), significant proportion of patients 
experience a recurrence of their disease (Ingle et al., 2010a). In addition, there is a 
high incidence of inter-individual variability with respect to tolerability to an extent 
that adverse effects like musculoskeletal complaints results in withdrawal of some 
patients from treatment (Ingle et al., 2010a; Lombard et al., 2016). This variability is 
believed to be due to a number of factors including potential inter-patients 
differences with respect to anastrozole pharmacokinetics and/or pharmacodynamics 
possibly due to their genetic variability (Edavana et al., 2013). It can therefore be 
conceived that the genetic variability in the genes that encode the drug target 
(aromatase) or drug metabolizing enzymes (CYP3A and UGT1A) could play a vital 
role in determining individual’s responses to anastrozole. 
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1.3 Research objectives 
 
General objective: 
To investigate the influence of CYP3A4 and CYP3A5 single nucleotide 
polymorphisms on anastrozole-associated adverse events and serum levels of 
anastrozole in post-menopausal breast cancer patients. 
 
Specific objectives 
 
The specific objectives are to: 
 
1. Develop a novel multiplex PCR-RFLP method for simultaneous genotyping of 
CYP3A4*4, CYP3A4*18B and CYP3A4*22 alleles in breast cancer patients 
2. Determine the allelic frequencies of CYP3A4*4, CYP3A4*18A, CYP3A4*18B, 
CYP3A4*22 and CYP3A5*3 in breast cancer patients 
3. Develop a newly validated HPLC detection method for anastrozole measurement 
in serum 
4. Determine the impact of CYP3A4*4, CYP3A4*18A, CYP3A4*18B, CYP3A4*22 
and CYP3A5*3 polymorphisms on anastrozole’s pharmacokinetics and 
pharmacodynamics 
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1.4 Research hypothesis 
 
It was hypothesized that the allelic and genotypic frequencies of CYP3A4*4, 
CYP3A4*18A, CYP3A4*18B, CYP3A4*22 and CYP3A5*3 among Malaysian breast 
cancer patients would vary from those commonly reported in the western countries 
and that these alleles may influence patients’ response to anastrozole treatment. To 
our knowledge, this is the first study to investigate the potential role of CYP3A4 and 
CYP3A5 genetic polymorphisms on inter-patient variability in response to treatment 
with anastrozole. 
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CHAPTER TWO 
LITERATURE REVIEW 
 
2.1 Breast cancer 
 
2.1.1 What is breast cancer? 
 
As simply defined by the American Cancer Society, breast cancer refers to a 
malignant (cancerous) tumour capable of invading the surrounding tissues or 
metastasizing to distant parts of the body (ACS, 2014). 
 
2.1.2 Breast cancer incidence 
 
Since 1990, in spite of the significant reduction in breast cancer mortality rates (by 
2.2% each year) in the developed countries (Toriola and Colditz, 2013), breast cancer 
persists as the most common malignant disease in women globally, with 1.3 million 
newly diagnosed cases and approximately 500,000 mortality annually (WHO, 2015). 
The yearly reported number of new cases had doubled over the last three decades 
(UK, 2013). The increased incidence is attributed to a number of factors which 
include longer life expectancy, improved detection techniques, altered reproductive 
patterns, higher prevalence of obesity globally and westernization of developing 
countries (ACS, 2014; WHO, 2015). 
 
In contrast to developed countries, where the incidence has stabilized or even 
reduced (Ravdin et al., 2007; Fontenoy et al., 2010; Gompel and Plu-Bureau, 2010), 
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the breast cancer incidence has accelerated in most Asian countries (including 
Malaysia) in the last two decades (Hirabayashi and Zhang, 2009; Pathy et al., 2011; 
GLOBOCAN, 2012). The local data has revealed that breast cancer is the most 
commonly occurring malignancy in Malaysian women (Ibrahim et al., 2012). In fact, 
Asian women have higher tendencies to be diagnosed at advanced stage of the 
disease when compared with their counterparts from the industrialized western 
Nations (Miao et al., 2014) where awareness is higher. For example, it has been 
reported that an estimated 10 – 20% of Asian breast cancer women would present 
with de novo advanced-stage breast cancer that has already metastasized, when 
compared with only 3 – 5% in the developed European Nations and the United States 
of America (Chopra, 2001; Sant et al., 2004; Tan et al., 2005; Yip et al., 2006; Lim 
et al., 2007). Another intriguing finding is that Asian women tend to have larger 
tumour size and metastatic lesions often involving multiple locations (Agarwal et al., 
2007) when detected. 
 
2.1.3 Pathogenesis and aetiological factors 
 
Breast cancer is a complex heterogeneous disease consisting of several entities with 
multiple histological and clinical features arising as a result of the interactions 
between the environment and an individual’s genetic makeup thus leading to 
mutations in the genes that are involved in regulation of cellular growth and 
functions (Borresen-Dale et al., 2010). Approximately 80% of breast cancers 
diagnosed affect women between 50 to 69 years old (Kaminska et al., 2015). The 
complexity of aetiology and pathogenesis of breast cancer has made it so 
unpredictable that only 20 to 30% of newly detected cases of breast cancer can be 
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traced to the various risk factors reported to be associated with its development 
(Kaminska et al., 2015). The commonest identifiable aetiological factors implicated 
in the pathogenesis of breast cancer are age, genetics, past history of breast diseases, 
positive history of cancer in first-degree family, early age at menarche, late age (after 
35 years of age) at birth of first child, diet, alcohol consumption, obesity, lifestyle, 
physical inactivity, endocrine factors and age at menopause (Bland, 1987; Tavani et 
al., 1999; Ali and Coombes, 2002; Kaminska et al., 2015). 
 
2.1.3.1  Age 
 
Although the incidence of breast cancer is low before 20 years of age, the incidence 
rate progressively increases with age and it has been estimated that by the age of 90 
years; 10% of women are affected (Russell RC, 2000). This is in line with the 
observation that reproductive hormones produced by the ovaries and the adrenal 
glands play important role in the pathogenesis of breast cancer; especially due to 
existing evidences that cancers which do not respond to hormones will not display 
any observable change in their incidence during the female reproductive age 
(Abdulkareem, 2013). Moreover, it is understood that both early age at menarche and 
late age at menopause contribute to the continuous and prolonged exposure to the 
detrimental effects of steroid hormones, which are believed to collaborate with other 
factors such as genetic and environment to promote breast cancer development 
(Aguas et al., 2005). 
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2.1.3.2  Gender 
 
Breast cancer is extremely rare in males (Russell RC, 2000) and is believed to be due 
to differences in hormonal exposure since it has been observed that male breast 
cancer also expresses oestrogen, progesterone and androgen receptors and men with 
klinefelter’s syndrome have been reported to show increased odds of having breast 
cancer (Murphy et al., 2006). 
 
2.1.3.3  Genetic factors 
 
Women with family history of breast cancer have increased chance of developing 
breast cancer when compared to the general population; and it has been documented 
that only about 5% of breast cancers are associated with a specific mutation (Russell 
RC, 2000). Dumitrescu and Cotarla have summarized the findings of a meta-analysis 
of 52 epidemiological studies which showed that 12% of breast cancer women have 
had at least one affected relative while 1% has had one or more relatives with breast 
cancer (Dumitrescu and Cotarla, 2005). 
 
Previously, a hereditary factor was suspected to play a role in susceptibility to breast 
cancer (Ford and Easton, 1995). Nevertheless, subsequent investigations revealed 
that between five to ten per cent of all breast cancers are caused by germline 
mutations in high-penetrance breast cancer susceptibility genes which include 
BRCA1, BRCA2, and p53; which make an individual more susceptible to hereditary 
breast cancer (Dumitrescu and Cotarla, 2005). The BRCA1 and BRCA2 genes are 
located on the long arm of chromosomes 17 and13 respectively and it has been 
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reported that gene-positive individuals have approximately 80% chance of 
developing breast cancer (Duncan et al., 1998; Russell RC, 2000; Winter et al., 
2016). 
 
2.1.3.4  Endocrine factors 
 
2.1.3.4.1 Endogenous 
 
Breast cancer is more frequently seen in women with infertility and those who have 
not breast-fed their infants (Abdulkareem, 2013). On the other hand, a woman that 
had a term pregnancy at an early age particularly if she had a late menarche and early 
menopause (factors that reduce the duration of exposure to oestrogen) has 
significantly reduced risk of breast cancer (Russell RC, 2000). Similarly, a woman 
with high parity (also believed to minimise prolonged exposure to oestrogen) has 
half the risk of having breast cancer when compared to a nulliparous woman (Russell 
RC, 2000). This is thought to be as a result of low circulating oestrogens during 
pregnancy. 
 
2.1.3.4.2 Exogenous 
 
Hormone replacement therapy (HRT) is an established risk factor for breast cancer 
particularly among current users of oestrogen and progestin for at least five years or 
above (Aguas et al., 2005). However, the HRT also has its own merit in relieving 
vaginal dryness and itching, tension headaches, mood disturbances, minimising the 
risk of osteoporosis and pathological fractures among other conditions 
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(Abdulkareem, 2013). The use of oral contraceptives has also been linked to a 
modest risk of breast cancer (Aguas et al., 2005). 
 
2.1.3.5  Diet and alcohol 
 
An increased risk of breast cancer has been observed with diets low in phyto-
oestrogens and heavy alcohol consumption (Russell RC, 2000; Dumitrescu and 
Cotarla, 2005). Similarly, diets rich in 35 – 40% of fat in calories (as seen with most 
western foods) increase the risk of breast cancer development. This is believed to be 
due to the presence of high cholesterol levels which is a precursor in oestrogen 
biosynthesis (Aguas et al., 2005). 
 
2.1.3.6  Lifestyle and physical activity 
 
The hormonal levels of plasma may be influenced by a combination of dietary 
factors along with exercise (Abdulkareem, 2013). These two factors either 
independently or together can affect a woman’s body mass index and it has been 
observed that obesity is a risk factor for breast cancer among post-menopausal 
women (Aguas et al., 2005). The likely explanation for this is the fact that fat 
deposits in adipose tissues tend to increase the circulating levels of oestrogens that 
are sourced from cholesterol (Abdulkareem, 2013). 
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2.1.4  Breast cancer classification 
 
Recent advances in molecular researches have changed the way breast cancer has 
been traditionally viewed as a single disease entity (Reis-Filho and Pusztai, 2011). 
To date, it is perceived as a collection of diseases with diverse anatomical 
characteristics, with variable clinical responses to therapy and prognosis (Sotiriou 
and Pusztai, 2009; Reis-Filho et al., 2010; Taherian-Fard et al., 2015). Therefore, in 
general, breast cancer classification falls into five systems of classification (Figure 
2.1), with the two most common forms of such classifications discussed below 
(sections 2.1.4.1 and 2.1.4.2). 
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Figure 2.1: Histopathological, anatomical, expression and genomic schemes for classification of breast cancers. Reproduced from 
Taherian-Fard et al., (2015) with permission by RightsLink.   
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2.1.4.1  Histological grading of breast cancer 
 
The most widely used grading system in breast cancer is the modified Bloom-
Richardson score (Taherian-Fard et al., 2015). This grading system utilises 
microscopic features of the tumour’s malignant cells relative to normal cells. It 
typically grades the tumour into grade 1-4. Briefly, Grade 1 tumour possesses cells 
that are very similar to the normal breast tissue and grade 2 tumour cells exhibit mild 
variation from the normal cells. On the contrary, Grades 3 and 4 tumours exhibit 
high dissimilarity with the normal breast tissue; such tumour cells have high 
proliferative capacity and metastasize faster than low-grade tumours (Meyer et al., 
2005). 
 
2.1.4.2  TNM staging  
 
The American Joint Committee on Cancer (AJCC) staging system is commonly 
employed to classify breast cancers (AJCC, 2014). The system uses three main 
features in the staging and include primary tumour (T), regional lymph nodes (N), 
and distant metastasis (M) collectively referred to as TNM classification. Based on 
these characteristics, breast cancer is grouped into five main stages (0 to IV) (Table 
2.1) 
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Table 2.1: TNM staging of breast cancer 
Stage Tumour size (T) Nodes involvement (N) Distant metastasis 
(M) 
0 Carcinoma in situ (Tis) None  None  
I Present but < 2.0 cm in 
its greatest dimension  
None None 
IIA Present but < 2.0 cm in 
its greatest dimension 
Metastasis to movable 
ipsilateral axillary lymph 
node 
None 
IIB From 2 to5 cm in its 
greatest dimension 
Either localized or spread 
to 1 – 3 axillary lymph 
nodes 
None 
IIIA At < 5 cm or none Spread to 4 – 9 axillary 
lymph nodes, fixed or 
matted 
None 
IIIB Tumour of any size with 
direct extension to chest 
wall or skin   
Either localized or spread 
to axillary lymph nodes 
None 
IIIC Any size metastasis in 10 or more 
axillary lymph nodes or in 
infra-clavicular lymph 
nodes, or clinically 
apparent ipsilateral 
internal mammary lymph 
node (s) in the presence of 
one or more positive 
axillary lymph node (s) 
None 
IV Any size Either localized or 
metastasis  to nearby 
lymph nodes 
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2.1.5 Oestrogens and aromatase enzyme in breast cancer 
 
One of the major physiological roles of oestrogen is regulation of mammary gland 
development (Lamote et al., 2004; Musumeci et al., 2015). Oestrogen receptors (ER) 
designated as ERα and ERβ are the main transducers of oestrogen biological activity. 
The ERβ is expressed in approximately 70% of breast tumours, while the bulk of 
breast tumours co-express both ERα and ERβ (Dotzlaw et al., 1997; Fuqua et al., 
2003; Huang et al., 2015). Interestingly, when ERα displays a growth stimulatory 
effect on breast cells, ERβ manifests the opposite effect by stimulating the anti-
proliferative and pro-apoptotic activities (Liu et al., 2002; Paruthiyil et al., 2004; 
Strom et al., 2004). 
 
The key enzyme involved in oestrogen biosynthesis is the aromatase which catalyses 
the final reaction in oestrogen formation (Gennari et al., 2011). The source of 
oestrogen varies significantly depending upon the menopausal status of a woman. In 
pre-menopausal period, the chief source of oestrogen is the ovary. Conversely, in 
post-menopausal period (when the production of oestrogen by the ovary ceases) 
oestrogen is synthesized in several locations including the adipose tissue, breast, 
brain, liver, and muscle (Simpson et al., 1994; Simpson, 2003; Gennari et al., 2011; 
Lonning et al., 2011). Consequently, the aromatase enzyme has a direct role on in 
situ oestrogen formation in the breast (Yue et al., 1998; Geisler, 2003) and is 
believed to play a vital part in the proliferation of breast cancer cells (Utsumi et al., 
1996; Chen et al., 2009). 
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2.1.6 HER2 and breast cancer prognosis 
 
Approximately 15-20% of all breast cancer tumours exhibit over-expression of 
human epidermal growth factor receptor (HER-2; neu; c-erB-2), a proto-oncogene 
that is linked to a poor prognosis and resistance to chemotherapy and hormonal 
treatment of breast cancer (Slamon et al., 1987; De Placido et al., 1998; Ross and 
Fletcher, 1998; Sun et al., 2015). The advent of anti-HER-2 therapy by using 
trastuzumab (herceptin), which binds to the HER2 extracellular domain, has 
effectively improved the outcome of HER2 positive breast cancer (De Laurentiis et 
al., 2005; Guarneri et al., 2010; Ahmed et al., 2015). However, as with other 
therapeutic agents, the incidence of trastuzumab-related adverse events especially 
cardiac toxicity is worrisome (Guglin et al., 2009; Tarantini et al., 2012; Advani et 
al., 2015; Bregni et al., 2015). Interestingly, attention has shifted to elucidating the 
solution to this adverse event, since a recent meta-analysis has revealed that HER2 
655 A > G polymorphism is associated with higher odds of developing trastuzumab-
associated cardiac toxicity (Gomez Pena et al., 2015). This phenomenon implies that 
in future this variant allele can be utilized to predict patients with higher risk of 
getting cardiac toxicity when receiving trastuzumab. 
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2.2 Anastrozole 
 
2.2.1 History 
 
The treatment of pre-menopausal breast cancer by bilateral oophorectomy was first 
introduced by Sir George Beatson in 1896 (Beatson, 1896). The 1950s and 60s 
witnessed focus on development of non-surgical alternatives to the surgical 
approaches in the treatment of breast cancer which include use of glucocorticoids, 
androgens and oestrogens (Lipsett and Pearson, 1957; Lipsett et al., 1957; Segaloff et 
al., 1963; Manni et al., 1977). 
 
Another strategy of direct inhibition of adrenal steroid synthesis was suggested by 
Ralph Cash which he thought could be an effective alternative to surgical removal of 
adrenals that was commonly used at that time to treat post-menopausal breast cancer 
(Cash et al., 1967). His suggestion was based on the fact that aminoglutethemide 
could block cholesterol side chain cleavage. The inhibitory effects of 
aminoglutethemide on the adrenals necessitated the use of replacement 
glucocorticoid, and therefore dexamethasone was selected for this purpose. However, 
it was soon observed that the efficacy of dexamethasone is affected by 
aminoglutethemide administration (Santen et al., 1974). To overcome this obstacle, 
hydrocortisone was substituted because it has no significant interaction with 
aminoglutethemide (Santen, 1981; Santen et al., 1990).  
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An earlier chance meeting by Siiteri and Santen led to the understanding that 
aminoglutethemide could effectively block the aromatase levels in the whole body of 
post-menopausal women (Santen et al., 2009). Prior to the meeting, in an in vitro 
study, Sitteri had previously shown in an in vitro study in 1969 that 
aminoglutethemide was capable of blocking aromatase (S Bolton, 1969) and was 
also conversant with the reports of Schwarzel and colleagues on AIs (Schwarzel et 
al., 1973). Sitteri and his colleagues later suggested that aminoglutethemide’s 
mechanism of action was most probably through inhibition of aromatase in breast 
cancer and they opined that further investigations were needed to elucidate this 
(MacDonald et al., 1967). This hypothesis was then tested and it was found that there 
was 95 – 98% aromatase inhibition in postmenopausal breast cancer women (Santen 
et al., 1978). This observation shifted the emphasis on the inhibitory activity of 
aminoglutethemide against aromatase and resulted in its subsequent classification as 
a “non-selective first generation” aromatase inhibitor (Cocconi, 1994; Dowsett and 
Coombes, 1994; Reddy, 1998; Goss and Strasser, 2001; Mokbel, 2002; Rose, 2003; 
Lonning, 2004; Gibson et al., 2007). 
 
As a result of the severe adverse effects associated with aminoglutethemide and 
failure to minimise them despite many efforts (Harris et al., 1983; Harris et al., 1984; 
Dowsett et al., 1985; Stuart-Harris et al., 1985), the need for selective aromatase 
inhibitors became necessary which led to the introduction of formestane (Coombes et 
al., 1984; Dowsett et al., 1987; Dowsett et al., 1989; Dowsett and Coombes, 1994; 
Chen et al., 2002). However, subsequent investigations revealed that formastane did 
not effectively block aromatase to be superior to aminoglutethemide and therefore 
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more efficacious inhibitors were sought (Coombes et al., 1984; Perez Carrion et al., 
1994; Geisler and Lonning, 2005). 
 
Identifying and appreciating the potential contributions of AIs in breast cancer 
treatment, a significant number of pharmaceutical companies took interest and 
considerably contributed to the discovery and development of more potent selective 
steroidal and non-steroidal AIs (Santen et al., 2009); this consequently gave rise to 
the emergence of fadrozole (CGS 16949A) which was the first agent to be 
categorized as second-generation aromatase inhibitor (AI) (Steele et al., 1987). 
Nevertheless, there was a setback when it was incidentally found to have inhibitory 
effects on aldosterone (Demers et al., 1990; Trunet et al., 1992). With more advances 
in research, the pharmaceutical companies explored structure/function evaluation and 
animal models among other strategies to develop the two new and popular non-
steroidal (anastrozole and letrozole) and one steroidal (exemestane) AIs (Santen et 
al., 2009) all of which received FDA approval and were demonstrated to have high 
potency and superior efficacy than aminoglutethemide, formestane and fadrozole and 
also possess less adverse drug reactions than aminoglutethemide and fadrozole (Goss 
and Strasser, 2001). Eversince the discovery of these important agents (AIs), the use 
of anastrozole as an alternative endocrine therapy for treatment of hormone-
responsive postmenopausal breast cancer has become a prevailing approach in the 
treatment of these cases (Zilli et al., 2009; Li and Shao, 2016).  
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2.2.2 Indication and dosage 
 
Until recently, tamoxifen has been the main adjuvant therapy for both pre- and 
postmenopausal ER+ early breast cancer cases (Montemurro et al., 2015; Li and 
Shao, 2016).  Although tamoxifen remains a valuable therapeutic option in both 
groups of patients (Pan and Chlebowski, 2014), its long term use was reported to be 
linked with potentially life-threatening adverse events such as high incidence of 
endometrial cancer, thromboembolism and cerebrovascular complications 
(Braithwaite et al., 2003; Fisher et al., 2005; Lewis, 2007; Perez, 2007; Ryden et al., 
2016). Besides this, certain cases of breast cancer can be primarily resistant to 
tamoxifen or may, in due course acquire resistance to the anti-oestrogen even if they 
formerly expressed significant amount of oestrogen receptors (Normanno et al., 
2005; Zilli et al., 2009; Hayes and Lewis-Wambi, 2015). 
 
As a result of the aforementioned concerns, the introduction of alternative endocrine 
therapies for treatment of endocrine-sensitive postmenopausal breast cancer was 
justifiable in making the blockade of aromatase activity a prevailing current approach 
in the treatment of these cases (Li and Shao, 2016). This therefore led to 
development of several AIs to either serve as an alternative to tamoxifien or to be 
used following some years of using tamoxifen. The use of third-generation AIs 
(anastrozole, exemestene and letrozole) is recommended by the current treatment 
guidelines since these agents are highly specific and efficient in blocking the 
aromatase activity and with relatively less adverse effects when compared with 
previous generations of AIs (Fabian, 2007; NCCN, 2012). 
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Anastrozole has been well recognized as the drug of choice for adjuvant treatment of 
both early- and advanced-stage postmenopausal breast cancer (Ingle and Suman, 
2005; Ingle, 2006). It has also been investigated in prevention of breast cancer 
among women at high risk of having the disease (Ingle, 2005). In terms of efficacy 
and adverse effects, anastrozole was compared with tamoxifen in the “Arimedex, 
tamoxifen alone or in combination trial (ATAC)” and was more effective but 
associated with lesser adverse events when compared with tamoxifen (Forbes et al., 
2008). Consequently, its use as adjuvant in the treatment of women with early-stage 
hormone-responsive breast cancer was approved in 2002 by the US Food and Drug 
Administration and is currently considered as the first-line drug of choice in the 
adjuvant setting (Behan et al., 2015). Interestingly, anastrozole was demonstrated to 
yield good results in the initial treatment setting (Forbes et al., 2008), following two 
to three years of tamoxifen (Boccardo et al., 2005; Jakesz et al., 2005; Kaufmann et 
al., 2007) and even in the extended adjuvant therapy following five years of 
tamoxifen therapy (Jakesz et al., 2007). 
 
In spite of the fact that anastrozole has been confirmed to be more effective than 
tamoxifen (Forbes et al., 2008), a significant population of patients still have breast 
cancer recurrence (Ingle et al., 2010a). Moreover, a considerable inter-patient 
variability in terms of toxicity has been observed to a level that adverse events such 
as musculoskeletal symptoms results in patients’ withdrawal from treatment 
(Lombard et al., 2016; Sahin et al., 2016). This variation is partly attributed to inter-
individual variability resulting from genetic variations that lead to differences in 
anastrozole’s pharmacokinetics and/or pharmacodynamics (Abubakar et al., 2014). 
